CompletedEarly Phase 1NCT04781309
NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy
Studying Progressive multifocal leukoencephalopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- Principal Investigator
- Irene CM Cortese, M.D.National Institute of Neurological Disorders and Stroke (NINDS)
- Intervention
- NT-I7(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2021 – 2025
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Collaborators
NeoImmuneTech
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04781309 on ClinicalTrials.govOther trials for Progressive multifocal leukoencephalopathy
Additional recruiting or active studies for the same condition.
See all trials for Progressive multifocal leukoencephalopathy →